| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.18(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kane Matthew R. |
President and CEO |
• • – |
2021-03-11 |
4 |
AS |
$11.38 |
$110,511 |
D/D |
(9,711) |
1,917,666 |
|
-9% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-03-11 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,927,377 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-03-10 |
4 |
AS |
$11.79 |
$114,481 |
D/D |
(9,710) |
1,905,863 |
|
-5% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-03-10 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,915,573 |
|
- |
|
| Barton Shane |
VP & Corporate Controller |
• – – |
2021-02-26 |
4 |
A |
$4.61 |
$5,965 |
D/D |
1,294 |
1,294 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2021-02-26 |
4 |
A |
$4.61 |
$12,668 |
D/D |
2,748 |
7,976 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-22 |
4 |
AS |
$12.04 |
$116,306 |
D/D |
(9,660) |
3,945,693 |
|
12% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-22 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,955,353 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-19 |
4 |
AS |
$11.55 |
$111,608 |
D/D |
(9,663) |
3,933,839 |
|
2% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-19 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,943,502 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-18 |
4 |
AS |
$12.20 |
$83,826 |
D/D |
(6,871) |
3,921,988 |
|
6% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-02-18 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,928,859 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-18 |
4 |
AS |
$12.23 |
$118,692 |
D/D |
(9,705) |
1,889,446 |
|
6% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-18 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,899,151 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-17 |
4 |
AS |
$12.28 |
$119,177 |
D/D |
(9,705) |
1,877,637 |
|
-2% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-17 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,887,342 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-16 |
4 |
AS |
$13.30 |
$128,970 |
D/D |
(9,697) |
1,865,828 |
|
-9% |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-02-16 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
1,875,525 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-29 |
4 |
AS |
$12.25 |
$78,939 |
D/D |
(6,444) |
3,907,345 |
|
-3% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-29 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,515 |
3,913,789 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-28 |
4 |
AS |
$11.97 |
$77,135 |
D/D |
(6,444) |
3,892,274 |
|
-4% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-28 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,898,718 |
|
- |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-27 |
4 |
AS |
$11.68 |
$82,321 |
D/D |
(7,048) |
3,877,204 |
|
-2% |
|
| Jantz Derek |
Chief Scientific Officer |
• • – |
2021-01-27 |
4 |
OE |
$0.04 |
$861 |
D/D |
21,514 |
3,884,252 |
|
- |
|
| Kane Matthew R. |
President and CEO |
• • – |
2021-01-26 |
4 |
AS |
$13.37 |
$129,649 |
D/D |
(9,697) |
1,854,011 |
|
-9% |
|
179 Records found
|
|
Page 6 of 8 |
|
|
0.29 (2.65%) 
